CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Net Cash Provided by (Used in) Operating Activities [Abstract]
Net loss	$ (48,417)	$ (28,162)
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Depreciation And Amortization	160	122
Amortization of notes and securities discounts	13,654	5,678
Stock-based compensation expense	42,713	1,977
Paid in kind interest	0	5,001
Change in fair value of warrants expense	(85,543)	2,173
Change in derivative liabilities	0	(14,232)
Accretion, net of amortization	52	(369)
Net realized losses (gains) on investment securities	(75)	35
Amortization of warrants	38	64
Amortization of debt issuance costs	6	34
Changes in operating assets and liabilities:
Accrued retrospective premiums	(19,350)	(14,344)
Other receivables	7,843	865
Other assets	12,931	591
Healthcare receivables	8,520	762
Operating lease right-of-use assets	881	797
Unpaid claims	13,606	12,467
Accounts payable and accrued expenses	(4,502)	(4,820)
Accrued salaries and benefits	6,874	271
Premium deficiency reserve	0	(4,282)
Other liabilities	151	2,066
Operating lease liabilities	(1,013)	(888)
Net cash used in operating activities	(92,869)	(37,176)
Net Cash Provided by (Used in) Investing Activities [Abstract]
Purchases of available-for-sale securities	(274,909)	(19,326)
Proceeds from Sale of Available-for-sale Securities	17,267	69,977
Proceeds from maturities of available-for-sale securities	265	32,101
Purchases of property and equipment	(99)	(242)
Net cash (used in) provided by investing activities	(257,476)	82,510
Net Cash Provided by (Used in) Financing Activities [Abstract]
Payment of notes payable principal	(5,020)	(4,496)
Issuance of common stock, net of early exercise liability	1,282	155
Proceeds from reverse capitalization, net of transaction costs	666,242	0
Acquisition of noncontrolling interest	0	3,903
Net cash provided by (used in) financing activities	662,504	(438)
Net increase in cash and cash equivalents	312,159	44,896
Cash and cash equivalents, beginning of period	92,348	67,598
Cash and cash equivalents, end of period	404,507	112,494
Supplemental Cash Flow Information [Abstract]
Cash paid during the period for interest	812	$ 1,306
Supplemental disclosure of non-cash investing and financing activities
Conversion of preferred stock to common stock	447,747
Issuance of common stock related to convertible debt	16,059
Capital contribution for extinguishment of debt	126,795
Issuance of common stock related to warrants exercised	97,782
Acquisition of Public and Private Warrants	147,582
Right-of-use assets obtained in exchange for lease liabilities	$ 101